Investigational drug · Phase 2
BZ371A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Female Sexual Arousal Disorder, Female Sexual Dysfunction (FSD).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "BZ371A"
First trial start
2026
Jul 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BZ371A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Female Sexual Arousal Disorder
- Female Sexual Dysfunction (FSD)
Largest trials
Live from ClinicalTrials.gov: studies naming "BZ371A" as an intervention, largest first.
- Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal DisorderPivotal-lookingNot yet recruiting
Biozeus Biopharmaceutical S.A.Industry
NCT06651541 · 174 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 30, 2027
Drug: BZ371A (0.5 ml); Placebo (0.5 ml) and 2 more · For: Female Sexual Arousal Disorder; Female Sexual Dysfunction (FSD)
Sites: Belo Horizonte, Brazil
- Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized PatientsStatus unknown
Biozeus Biopharmaceutical S.A.Industry
NCT05558007 · 72 participants (planned) · Start Nov 22, 2023 · Primary completion Dec 31, 2024
Drug: Tadalafil 5mg; BZ371A and 2 more · For: Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction; Prostate Cancer and 1 more
Sites: Belo Horizonte, Brazil
- Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal DisorderStatus unknown
Biozeus Biopharmaceutical S.A.Industry
NCT06116045 · 30 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 1, 2025
Drug: BZ371A 7.5 mg (1.5 ml); BZ371A 5.0 mg (1.0 ml) and 4 more · For: Female Sexual Arousal Disorder; Female Sexual Dysfunction
Sites: Rio de Janeiro, Brazil
- Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically AdministeredCompleted
Biozeus Biopharmaceutical S.A.Industry
NCT05332340 · 12 participants · Start Nov 16, 2022 · Primary completion Nov 30, 2022
Drug: BZ371A · For: Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction; Prostate Cancer and 1 more
Sites: Valinhos, Brazil
Newest research
PubMed records naming it or its code names, newest first.
- Targeting female sexual arousal disorder: Therapeutic potential of the Phoneutria nigriventer venom-derived peptide PnPP-19 (BZ371A).
Moreira JA, da Silva CN, Pereira de Almeida AA, et al. · Toxicon 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.